Novel probes, carriers and prodrugs to target senescent cells in vivo

• Autores: Beatriz Lozano Torres
• Directores de la Tesis: Félix Sancenón Galarza (dir. tes.), Ramón Martínez Máñez (dir. tes.)
• Lectura: En la Universitat Politècnica de València ( España ) en 2021
• Idioma: español
• Tribunal Calificador de la Tesis: Enrique Victor García-España Monsonís (presid.), Raúl Pérez Ruiz (secret.), Elisabete de Jesús Oliveira Marques (voc.)
• Programa de doctorado: Programa de Doctorado en Química por la Universitat de València (Estudi General) y la Universitat Politècnica de València
• Materias:
  • Química
    • Química analítica
      • Fluorimetría
  • Ciencias de la vida
    • Antropología (física)
      • Envejecimiento somático
• Enlaces
  • Tesis en acceso abierto en: RiuNet
• Resumen

  • The doctoral thesis entitled "New probes, carriers and pro-drugs directed to senescent cells in vivo" focuses on the development and evaluation of probes based on functionalized fluorophores or nanoparticles, as well as on the development of prodrugs, applied to the field of cellular senescence.

    First, the different concepts related to sensing and cell sescence are introduced, addressing the need for new diagnostic and therapeutic tools for these diseases. Chapters three and four describe a new two-photon molecular probe for in vivo senescence detection in mice with tumor xenografts treated with senescence-inducing chemotherapy, another probe for in vivo detection in an orthotopic mouse breast cancer model. treated with senescence-inducing chemotherapy, and in a mouse model of renal fibrosis. Chapter five focuses on a new concept of non-invasive molecular probes, which provide an easily readable signal through simple measurements of urine fluorescence. Finally, regarding the detection of cellular senescence, chapter six presents the in vivo detection of cellular senescence through the controlled release of Nile Blue in mesoporous silica nanoparticles functionalized with a galactohexasaccharide. Once the planned objectives with regard to diagnosis had been achieved, chapter seven addressed the improvement of one of the most powerful and widely known senolytics in the field of cellular senescence that exists on the market today: Navitoclax.